Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

ACE/NEP inhibitors claimed by Fujisawa

April 26, 1996

BMS's ACE/NEP inhibitors in phase I

April 26, 1996

Yamanouchi selects YM-471 for clinical development

April 19, 1996

Corvert now available in U.S.

April 19, 1996

Posicor submitted for approval

April 19, 1996

New ETA antagonist from SmithKline Beecham: SB-225757

April 19, 1996

EMD-94246, promising endothelin antagonist for hypertension

April 19, 1996

Zanidip approved for marketing in U.K.

April 19, 1996

CP-191166, angiotensin II antagonist from Pfizer

April 19, 1996

YM-087 in phase I for CHF

April 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...